Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespi, Gabriela A. N., Hermans, Stefan J., Parker, Michael W., Miles, Luke A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549621/
https://www.ncbi.nlm.nih.gov/pubmed/25880481
http://dx.doi.org/10.1038/srep09649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549621/
https://www.ncbi.nlm.nih.gov/pubmed/25880481
http://dx.doi.org/10.1038/srep09649

Ejemplares similares